Wednesday, August 3, 2016

180 ...

... days of notice of a drug's impending launch must be provided by biosimilar manufacturers to the reference drug company after the FDA has approved the biosimilar, according to a recent Federal Circuit Court of Appeals decision in Amgen Inc. v. Apotex Inc.

No comments:

Post a Comment